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Abstract
High Throughput Biological Data (HTBD) requires detailed analysis methods and from a life science perspective, these
analysis results make most sense when interpreted within the context of biological pathways. Bayesian Networks (BNs)
capture both linear and nonlinear interactions and handle stochastic events in a probabilistic framework accounting for
noise making them viable candidates for HTBD analysis. We have recently proposed an approach, called Bayesian Pathway
Analysis (BPA), for analyzing HTBD using BNs in which known biological pathways are modeled as BNs and pathways that
best explain the given HTBD are found. BPA uses the fold change information to obtain an input matrix to score each
pathway modeled as a BN. Scoring is achieved using the Bayesian-Dirichlet Equivalent method and significance is assessed
by randomization via bootstrapping of the columns of the input matrix. In this study, we improve on the BPA system by
optimizing the steps involved in ‘‘Data Preprocessing and Discretization’’, ‘‘Scoring’’, ‘‘Significance Assessment’’, and
‘‘Software and Web Application’’. We tested the improved system on synthetic data sets and achieved over 98% accuracy in
identifying the active pathways. The overall approach was applied on real cancer microarray data sets in order to investigate
the pathways that are commonly active in different cancer types. We compared our findings on the real data sets with a
relevant approach called the Signaling Pathway Impact Analysis (SPIA).
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Introduction
Bayesian Network (BN) models have gained popularity for
learning biological pathways from microarray gene expression
data [1,2]. BNs represent dependency structure for a set of
random variables using directed acyclic graphs and have been
used with increasing popularity in mathematics and computational
sciences over the past 20 years. However, current BN applications
are limited to structure learning using observed data and therefore
work only on a few hundreds of variables as structure learning
algorithms are computationally complex. This, in turn, results in
inefficient use of HTBD, which contain a much larger number of
variables.
From a life sciences perspective, data analysis results make most
sense when interpreted within the context of biological networks
and pathways. Previously established individual gene analysis
based methods have been extended to network and pathway scale
mostly along the lines of gene set analysis (GSA) [3,4] or Gene
Ontology (GO) based approaches [5–7], which focuses on
determining predefined gene sets or classes that are significantly
regulated. However, these approaches consider the input genes
and the target gene sets and classes simply as lists and do not
incorporate in their models the topology via which genes in these
classes interact with each other. Other popular commercial
approaches, such as the Ingenuity Pathway Knowledge Base
(Ingenuity Inc., California) or PathwayAssist (Ariadne Genomics,
California) also identify known pathways as active based on
HTBD simply by considering the number of genes shared by the
input list and the target pathway. All aferomentioned methods use
some variation of the main idea that a functional class is relevant
to the observed HTBD if the class possesses a statistically
significant amount of the input gene list.
We have recently proposed an approach, called Bayesian
Pathway Analysis (BPA), for analyzing HTBD using BNs [8]. In
the BPA framework known pathways are modeled as BNs and the
processed HTBD is used to score each network to assess its fitness
to the observed data; achieving a workflow that incorporates in its
model the topology of the pathways. There have since been
approaches that model the pathway topology to some degree in
the analysis of HTBD [9–14]. In terms of general applicability and
direct relation to the output of BPA, we have used the Signaling
Pathway Impact Analysis (SPIA) [15] in our comparisons. SPIA
combines the GSA based pathway activation measure with a novel
pathway perturbation score, which reflects the degree to which the
deregulation of the genes in the pathway is in concordance with
the signaling hierarchy.
In the BPA approach, pathways are retrieved from the KEGG
database [16]. Each entry (node) in the pathway is mapped to an
internal unique ID and a conversion module carries out the
necessary mapping between the input gene expression IDs and the
pathway node IDs. Repeating entries in the pathway are merged
and represented as a single node while conserving edge relations.
BN theory utilizes Directed Acyclic Graphs (DAG) but there may
exist cycles in the biological pathways. This is overcome using
Spirtes’ method where graph representations of structural
equation models [17] are converted to collapsed acyclic graphs
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such that d-separations in the collapsed graph entail the same
independency relations defined by the model. To this end, a
biological pathway is modeled as a BN, which now can be tested
against input data to assess its fitness.
BPA assumes a two-group (e.g. case vs. control) normalized
gene expression data as input. The observation matrix to score
each DAG is obtained by generating the fold change (FC) values
for each pair of samples in the two groups. In this matrix, columns
represent genes in the DAG and rows represent pairwise
comparisons. If there are N1 and N2 samples in the two groups,
the observation matrix consists of N16N2 rows. Each column
represents the FC for the corresponding gene in each of the
N16N2 pairwise comparisons. These continuous FC values are
discretized using a cut-off of 2. If the FC value is greater than 2 or
less than 0.5 (i.e. the gene is deregulated), it is converted into 1,
and otherwise it is converted into 2.
The degree to which a pathway explains given HTBD is
measured using the Bayesian Dirichlet equivalent (BDe) score with
equivalent sample size method [18]. In this phase, the BN is
updated with the observation matrix during the score calculation.
Statistical significance of this measurement is assessed by testing it
against datasets generated by applying randomization via boot-
strapping where the observed score is ranked against scores
obtained from randomized data sets. Bootstrapping is applied to
the columns of the observation matrix providing a randomization
of the rows, which are used in scoring. The results are evaluated in
terms of nominal p-values and false discovery rate (FDR) values
correcting for multiple hypotheses testing.
In this paper, we have two fundamental aims. Our first aim is to
improve on the BPA system by using the following strategies. In
order to optimize the discretization phase, we tried Equal Width,
Equal Frequency, K-means, Column K-means, Bi-directional K-
means, and Automatic Threshold Discretization [19,20] in
addition to the hard-cut-off levels offered by BPA. In the scoring
phase, we applied Akaike Information Criterion (AIC) [21],
Bayesian Information Criterion (BIC) [22], and Factorized
Normalized Maximum Likelihood (fNML) [23] and compared
the results with the BDe scoring scheme. The significance
assessment phase was changed so that random data sets were
obtained at the gene signal level. In this approach, samples in each
of the two classes are randomly permuted to provide new data sets
[24]. Each new data set (with new class assignments for each
sample) is run through the complete workflow and a score value is
calculated. This way, we overcome the cases where the current
BPA approach fails to provide randomized data sets. In testing
these new approaches, we generated synthetic microarray data
that simulates gene expression from N pathways where a subset,
Na, of these pathways is active. A performance criterion is assessed
by the accuracy of predicting active and passive pathways. In
addition to improving the memory and CPU usage of the
algorithm, we also added new organisms for which the BPA system
can be used and we provide a web portal at http://bioinfo.unl.
edu/bpa/ which hosts the stand-alone version of the optimized
software along with a tutorial and example data sets.
Our second aim in this study is to apply the improved pathway
analysis approach on real cancer data sets. For this purpose, we
downloaded real microarray data sets from the NCBI’s GEO
database regarding bladder, brain, breast, colon, liver, lung,
ovarian and thyroid cancers. We investigated the pathways that
are commonly identified as active in these various cancer
microarray data sets.
Methods
Class Label Permutation
In the original BPA system, the observation data matrix for BN
scoring is composed of the 2-level discretized FC levels for the
genes in the network to be scored. The degree to which a pathway
explains given HTBD is measured using the ‘‘Bayesian Dirichlet
equivalent’’ (BDe) score and the statistical significance of this
measurement is assessed by randomization via bootstrapping
where the observed score is ranked against scores obtained from
randomized data sets. Randomized data sets are obtained by
changing the structure of the columns of the observation matrix
via sampling with replacement of each column separately.
In Table 1, we show two sample instances of such input
matrices. Here, columns denote the genes and rows denote the
pairwise comparison of the samples in the two sample groups (e.g.
cancer vs. normal). The aferomentioned randomization method
(originally employed by BPA) works successfully when an
observation matrix as in Table 1 (a) is the case where a given
column does not consist only of one type of observation. However,
if the observation matrix turns out to be as in Table 1 (b), where
columns represent only one type of observation, randomizing the
columns of the observation matrix will not result in any change.
Therefore, the scores obtained by randomized data sets will be the
same, making the significance assessment almost impossible to
achieve. It is possible to obtain matrices as in the latter case, i.e. a
matrix where a given column consists only of the same level, when
a gene shows the same degree and direction of change between the
two classes. In other words, if a gene in a given pathway is
consistently 2 or more FC upregulated in one class versus the
other, we would end up having the column for this gene to consist
only of the same discretization level.
In order to overcome this problem, we applied the permutation
method previously described to randomize gene expression data
sets [24]. This randomization is done by replacing the samples of
each class randomly. Suppose we have a dataset composed of 10
normal and 10 cancer samples. In one instance of the permuta-
tion, for example, 3rd, 5th, and 6th normal samples are replaced
with 1st, 7th, and 9th cancer samples. The observation matrix is
generated by pairwise comparison of the signal values over the
new order of two classes followed by discretization. This procedure
is repeated B times and pathway scores are calculated using the
discretized matrices. As a result, the statistical significance of the
observed score can be assessed accurately via ranking against
scores obtained from different observation matrices generated by
these B randomized data sets. If the score of a given pathway is Sn,
its p-value is assessed using
P Snð Þ~ 1
B
XB
k~1
I SkwSnð Þ
where I(a) is 1 if a is ‘‘true’’ and 0 otherwise. The significance of
each pathway is reported as this nominal p-value and the
corresponding false discovery rate (FDR) calculated using the
Benjamini-Hochberg procedure [25]
Discretization
BPA utilized a discretization method such that the continous FC
value is represented as 1 if it’s greater than 2 or less thanK (i.e. a
gene is dysregulated), and as 2 otherwise. Another use of the 2-
level discretization is choosing a cut-off value of 3, i.e., the FC is
represented as 1 if its value is greater than 3 or less than 1/3 and as
2 otherwise. In 3-level discretization with the cutoff value 2, the
Bayesian Pathway Analysis
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fold change is represented as 1 if its value is greater than 2, as 2 if
less than K, and as 3 otherwise. In 3-level discretization with the
cut-off value of 3, the fold change is represented as 1 if its value is
greater than 3, as 2 if less than 1/3, and as 3 otherwise.
In this study, we propose new discretization methods [19,20] to
be utilized in processing the observed fold change values for use by
Bayesian scoring metrics. An N-by-M matrix E is used to denote
the observed FC matrix, where N is the number of pairwise
comparisons and M is the number of genes. E(n,m) denotes the
FC value of comparison n for the gene m. E(n,:) denotes FC data
of comparison n for all genes, and E(:,m) denotes the FC data of
gene m for all the comparisons.
Equal Width Discretization (EWD). EWD divides the
observation matrix row n into k intervals of equal width between
E(n,:)min and E(n,:)max. Thus the intervals of comparison n have
width w= (E(n,:)max - E(n,:)min)/k, with boundary points at
E(n,:)min +w, E(n,:)min +2w, …, E(n,:)min + (k - 1)w where k is a
positive integer.
Equal Frequency Discretization (EFD). EFD divides the
sorted E(n,:) into k intervals so that each interval contains the
same number of FC values.
K-means Discretization. K-means divides E(n,:) into k
intervals by k-means clustering so that similar FC values of
comparison n are placed in the same interval.
Column K-means Discretization (Co-k-means). Co-k-
means divides E(:,m) into k intervals by k-means clustering so
that similar FC values for the gene m are placed in the same
interval.
Bidirectional K-means Discretization (Bi-k-means). In
the bi-k-means method both k-means and co-k-means are
respectively implemented with parameter k+1, giving every FC
value two discretized values. If the product of the two values is
equal to or greater than x2, and less than (x+1)2, the final
discretized value of this expression value is x, where x is a positive
integer ranging from 1 to k.
Automatic Threshold Discretization. There are two op-
tions for the automatic threshold discretization, which iteratively
determines the cut-off values by minimizing the variance. The
whole FC data E is divided into two intervals according to a
certain cut-off value in the global option. The local option of this
method divides E(:,m) into two intervals according to the cutoff
values defined for each column (gene) separately.
Scoring
In addition to the BDe scoring scheme, we propose the
following score metrics to be used in the BPA system.
Akaike Information Criterion (AIC). AIC is one of the
most commonly used information criteria, which selects the model
that minimizes the negative likelihood penalized by the number of
parameters [21]:
AIC M,Dð Þ~ log P^ DDMð Þ{p
whereP^ DDMð Þ is the maximum likelihood of the model M, D is
observed data, and p is the number of parameters in the model.
Bayesian Information Criterion (BIC). BIC is another
widely used information criteria and unlike AIC, BIC is consistent
and improves in performance with large sample sizes [22]. BIC is
defined as:
BIC M,Dð Þ~ log P^ DDMð Þ{ p
2
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BIC differs from AIC only in the second term, which depends
on the sample size N.
Factorized Normalized Maximum Likelihood
(fNML). Silander et al. [23] developed the fNML score based
on the normalized maximum likelihood (NML) distribution
[26,27]. Given a data set D, the NML model selection criterion
chooses the model M for which PNML DDMð Þ is largest.
PNML DDMð Þ~ P^ DDMð ÞX
D’
P^ D’DMð Þ
where the normalization is done over all data sets D9 of the same
size as D. After taking the logarithm, the score is in a form of
penalized log-likelihood given G= {G1,…,Gm} as the parent set in
the DAG (i.e. Gi is the parent set of the node Xi in the DAG):
SfNML Di,DGi
 
~ logPNML Di D Gi
 
~ log P^ Di D Gi
 
{ log
X
D ’i
P^ D’i D Gi
 
where the normalizing sum goes over all the possible Di column
vectors. Even though the penalty term has an exponential number
of terms, it can be evaluated efficiently using a linear-time
algorithm introduced in [28]. By calculating the penalty term for
each variable in the dataset, the NML becomes factorized.
Data Sets
We generated synthetic transcriptional regulatory networks and
produced simulated gene expression data with noise using
SynTReN v1.12 [29]. We created 55 synthetic networks that
mimic biological pathways with sizes ranging from 7 to 200. We
randomly selected 20 out of 55 pathways to be active and
SynTReN generated the corresponding expression datasets for 20
test and 20 control samples with 2249 genes adding a 4% noise
level.
To test the optimized and improved BPA performance on real
data sets, we used 1 bladder, 2 brain, 2 breast, 1 colon, 2 liver, 1
lung, 1 ovarian, and 2 thyroid cancer data sets. In choosing the
data sets, we fixed the platform to be Affymetrix to prevent bias
and used data sets where tumor and normal samples are clearly
defined and the cancer samples are as homogenous as possible.
Most of the chip data came from the Affymetrix HG-U133 Plus
2.0 GeneChip, which is composed of more than 54,000 probe sets
representing over 47,000 transcripts providing a comprehensive
picture of the human transcriptome. Other chip types include HG-
U133A and HG-U133A_2, which represent approximately 22,000
probesets. Prior to application of the proposed approach, raw
microarray data has been normalized using Affymetrix Microarray
Analysis Suite (MAS) 5.0 algorithm [30].
For each data set, we applied the proposed analysis method with
1000 permutations and assessed significant pathways with a
nominal p-value of 0.05 and an FDR of 0.25.
Results
In Table S1, we list the accuracy levels (if a network is correctly
called active/inactive) of the different discretization schemes for 10
simulated datasets (D1–D10). According to the simulation results,
the best discretization method is the 2-level k-means discretization
applied to the rows of the observation matrix. This approach
achieves an accuracy of 0.96260,031. Therefore, 2-level k-means
method is used as the discretization method for the experiments to
determine the best scoring criterion.
The datasets, which are used for the performance measurement
of discretization methods, are also used for the assessment of the
scoring methods. The obtained prediction accuracies are listed in
Table 2. According to the simulation results, the best scoring
method is the fNML method, which estimates whether a pathway
is active or not with an accuracy of 0.98460,016. Therefore, the
2-level k-means discretization and fNML scoring methods are used
for the real microarray data analysis as this combination achieved
the highest accuracy.
In Table 3, we list the 12 real cancer microarray data sets (GEO
Numbers, cancer types, and numbers of samples) and the number
of pathways identified as active by BPA and SPIA analyses. In
Tables S2 and S3, we list the complete list of pathways deemed
active by the BPA and SPIA methods for each real cancer
microarray dataset, respectively. In total, BPA identified 171
pathways that have been found significant in at least one of the
data sets. 15 of these pathways have been found to be significant in
at least half of the data sets and therefore potentially represent
mechanisms common to different cancer types (see Table S2).
We also investigated the commonality of significant pathways in
cancer types represented by two data sets except for the thyroid
cancer, which has resulted in very few significant pathways. These
results for the BPA analysis are summarized in Figure 1. In the
case of brain and liver cancer data sets, the common pathways
consist of 52% and 59% of the dataset with the smaller number of
pathways. In the breast cancer data sets, we see a lesser degree of
agreement (,31%). These commonalities are 60%, 41%, and
52% for the brain, breast, and liver datasets, respectively, using the
SPIA analysis. However, SPIA uses a subset of the pathways
investigated by the BPA system. When we consider only the
pathways in the SPIA database, the commonalities in the BPA
analysis are 73%, 45%, and 71% for the brain, breast, and liver
datasets, respectively.
In Figure 2, we list the number of pathways identified by the
two analysis methods when the pathway database is restricted to
the one used by SPIA. On average, the number of pathways found
to be significantly active by both methods is about 60% of the
pathways of the algorithm with the smaller number of active
pathways.
Although the improved BPA system outperformed the old BPA
system on synthetic data sets (data not shown), we compared the
performance of both methods on the real cancer microarray data.
The list of pathways deemed significant by the old BPA system is
represented in Table S4. The old BPA analysis revealed 127
pathways active in at least one of the cancer data sets and 18 of the
pathways were found to be common to at least half of the data sets.
In Table S5, we list the numbers of pathways identified as active
by both BPA systems and indicate the number of pathways
commonly identified by the two methods in each cancer data set.
These results on the real cancer data sets (Tables S4 and S5)
indicate that the old BPA system fails to exhibit consistency for
some of the datasets (e.g. 57 vs. 1 pathway identified by the new vs.
old PBA in the ‘‘bladder’’ data set; 16 vs. 3 pathways identified by
the new vs. old PBA in the ‘‘breast’’ data set; 58 vs. 0 pathway
identified by the new vs. old PBA in the ‘‘lung’’ data set; and 10 vs.
0 pathway identified by the new vs. old PBA in the ‘‘thyroid’’ data
set). We believe this is mainly due to the permutation test method
introduced in the new BPA system where the old system fails to
generate randomized data sets in pathways showing a constant
fold change direction for its members (see Table 1). Some of the
performance improvement can be attributed to the optimized
discretization and scoring methods incorporated in the new BPA
system. The old and new BPA sytems show, on average, a 28%
overlap between the pathways identified in each data set. This
Bayesian Pathway Analysis
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level of agreement is significantly lower than the one observed
between the new BPA and SPIA methods, which showed 60%
overlap on average. Moreover, we obtained a 25% overlap on
average between the old BPA and SPIA methods when the
pathways identified for each real cancer microarray data set by the
two methods were considered.
We also applied the improved BPA method on the NCI-60
cancer cell line microarray data set used in describing the Gene
Set Enrichment Analysis (GSEA) method [31]. This data set
contains microarray results (run on the Affymetrix HGU95Av2
platform) for 50 of the NCI-60 cell lines (www.broadinstitute.org/
gsea/datasets.jsp). We used this data set to identify pathways
deregulated following a mutation in the tumor suppressor p53
gene. Out of the 50 samples, 17 are wild type and 33 carry
mutations in the p53 gene. The pathways identified as active by
BPA due to the mutations in p53 are listed in Table 4.
Discussion
Our synthetic data simulations identified k-means clustering as
the best performing discretization method. We find this result
reasonable as k-means uses the distribution in the data to minimize
the total mean squared error with respect to the discretized values
and the real FC occurrences. Also based on the synthetic data
results, the scoring method that yielded the highest accuracy was
the factorized normalized maximum likelihood (fNML) score [23].
This result was also expected as it has been shown that the BDe
scoring scheme is very sensitive to the choice of prior hyper-
parameters and AIC and BIC require some manual parameter
setting and do not work well with small data sets, which is
occasionally the case with HTBD [32]. fNML on the other hand is
an information theory based optimized scoring method that has no
tunable parameters.
In the real microarray data analysis using BPA, the pathway
that came out in most of the cancer data sets as significantly active
Table 2. Prediction accuracy of different scoring methods on synthetic datasets.
BDe AIC BIC fNML
D1 0.945 0.964 0.909 1.000
D2 0.982 1.000 0.927 0.964
D3 0.982 1.000 0.945 1.000
D4 0.964 0.982 0.982 1.000
D5 0.945 1.000 0.891 1.000
D6 0.945 0.982 0.982 0.964
D7 0.982 0.982 0.927 0.982
D8 1.000 0.982 0.964 0.982
D9 0.982 0.982 0.927 0.982
D10 0.891 0.945 0.945 0.964
Avg 0.962 0.982 0.940 0.984
SD 0.031 0.017 0.030 0.016
BDe: Bayesian Dirichlet Equivalent; AIC: Akaike Information Criterion; BIC: Bayesian Information Criterion; fNML: factorized Normalized Maximum Likelihood.
doi:10.1371/journal.pone.0102803.t002
Table 3. Cancer Data Sets and numbers of active pathways Identified by BPA and SPIA analyses.
GEO# (GSE) Cancer Type Chip Type (HG-U133) # of Samples BPA SPIA
7476 bladder Plus2 12 (9C, 3N) 57 40
12907 brain A 25 (21C, 4N) 81 23
15824 brain Plus2 35 (30C, 5N) 46 32
8977 breast Plus2 22 (7C, 15N) 16 25
22544 breast Plus2 18 (14C, 4N) 66 36
41328 colon Plus2 20 (10C, 10N) 36 39
14520 liver A2 43 (22C, 21N) 77 22
14323 liver A2 66 (47C, 19N) 59 17
10799 lung Plus2 19 (16C, 3N) 58 43
14407 ovarian Plus2 24 (12C, 12N) 5 18
3678 thyroid Plus2 14 (7C, 7N) 4 27
6004 thyroid Plus2 18 (14C, 4N) 10 27
doi:10.1371/journal.pone.0102803.t003
Bayesian Pathway Analysis
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(8/12) is the Cell adhesion molecules (CAMs) pathway. CAMs are
located on the cell surface and participate in the activity of a cell
binding with other cells. One of the primary features of cancer
cells is uncontrolled growth where the cells are immune to density-
dependent inhibition. Cancer cells keep on growing, forming
multiple levels, even when the cell density is increased. This is
mainly due to the malfunctioning in CAMs, which has been shown
to play an important role in cancer progression [33] and
disrupting important signal-transduction pathways [34]. Specifi-
cally, CAMs have been shown to be involved in brain [35],
bladder [36], breast [37], liver [38], lung [39] and thyroid [40]
cancer; the cancer data sets where the proposed system found the
CAM pathway as significantly activated.
Other pathways that need to be emphasized are ‘‘Citrate
(TCA/tricarboxylic acid) cycle’’, ‘‘Complement and coagulation
cascade’’ and ‘‘Adipocytokine signaling’’ pathways that are found
to be significantly active in 7 cancer data sets out of 12. Citrate
cycle, also known as the tricarboxylic acid cycle (TCA cycle) or the
Krebs cycle, is part of cellular respiration. It is a series of chemical
reactions used by all aerobic organisms to generate energy. Its
central importance to many biochemical pathways suggests that it
was one of the earliest parts of cellular metabolism to evolve [41].
A recent study identified this cycle as a cancer-specific metabolic
pathway [42]. In a wide range of tumor cells including the types
included in our datasets, it is found that a mutation causes this
cycle to run in reverse. Complement and coagulation cascade
pathway can be explained in two parts: the complement system is
a proteolytic cascade in blood plasma and a mediator of innate
immunity, a nonspecific defense mechanism against pathogens,
and blood coagulation is another series of proenzyme-to-serine
protease conversions. This pathway is identified as significant for
breast and liver cancer types in a functional cancer map, which
has been established following the analysis of functional expression
profiles of significantly enriched KEGG pathways across different
tumor entities assigned to various tumor classes [43]. Adipocyto-
kine signaling pathway is positively correlated with leptin
production, which is an important regulator of energy intake
and metabolic rate. Leptin and adiponectin are the most abundant
adipocytokines and the best-studied molecules in this class so far.
Recent tumor biological findings on the role of the most
prominent adipocytokines leptin and adiponectin, which are
involved in tumor growth, invasion and metastasis, show the
effects of adipocytokines to brain and breast cancers [44], the types
of cancer datasets where the BPA system found this pathway as
significantly activated. There have been other additional studies
that have shown the relation of adipocytokine signaling pathway to
lung and liver cancers [59,60].
Our synthetic data results show that the improved BPA system
identifies the activity of a pathway with over 98% accuracy.
Although there is no gold standart in assessing the active pathways
regarding the real microarray data of a certain phenotype, BPA’s
reproducibility in the same cancer types has been over 50% in
average. When the pathway database is limited to the one used by
SPIA, this reproducibility exceeds 70%. Finally, when all the
cancer datasets are considered, the agreement between the two
methods is around 60%. Given the technical and biological
Figure 1. Commonality of significant pathways using the BPA analysis on the same cancer types.
doi:10.1371/journal.pone.0102803.g001
Figure 2. Number of pathways found significant in real microarray data sets using BPA and SPIA methods.
doi:10.1371/journal.pone.0102803.g002
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variation, such a high degree of overlap between different pathway
analysis schemes is very promising.
In an attempt to identify patways specific to particular cancer
types, we investigated pathways that are consistently found to be
active for the same cancer types (and non-active for the other
cancer types) by the current BPA system. For brain cancer,
‘‘Parkinson’s disease pathway (hsa05012)’’ was found active in
both brain cancer data sets and only in one of the remaining 10
cancer data sets. Parkinson’s disease (PD) is one of the most
common neurodegeneretive disorders associated with cell loss in
the substantia nigra region of the midbrain [45]. Recently, there
have been studies that link the molecular mechanisms and genetic
dispositions of the disease to cancer. Mutations in PARK2, one of
the most common causes of early-onset PD, has been shown to
play a central role in glioblastomas [46] exhibiting changes in
almost identical residues in both the PD and the brain cancer
samples. Identification of this pathway as active almost uniquely
and consistently in brain cancer data sets implies that BPA is able
to identify biologically meaningful pathways based on the
underlying HTBD. In the liver cancer data sets, ‘‘Biotin
metabolism (hsa00641)’’ and ‘‘3-Chloroacrylic acid degradation
(hsa00780)’’ pathways were found to be active only in the two liver
data sets. Biotin concentration is known to be high in cancerous
tumors compared to normal tissues and biotin and other water-
soluable vitamin B metabolisms have been shown to be important
in hepatocellular carcinoma [47,48]. Similarly, 3-Chloroacrylic
acid degradation pathway has been shown to be active in
hepatocellular carcinoma [49,50].
Comparison of the old BPA system with the improved one
proposed in this paper on the real cancer microarray data sets
revealed that the old BPA system fails to identify pathways for
some data sets and provides less biologically meaningful pathways
showing insignificant agreement with the improved BPA and SPIA
methods. Moreover, we see a less degree of agreement for the
same cancer data sets in the old BPA system. For example, the old
system identified only 3 pathways in one of the ‘‘brain’’ data sets
compared to 122 pathways identified for another data set for the
same cancer type. These differences are very likely due to the
improved randomization, discretization, and scoring strategies
introduced in the current BPA system.
Pathways that have been identified as significantly activated by
BPA due to a p53 mutation are listed in Table 4. p53 is known to
be involved in ‘‘melanogenesis’’ (hsa04916) through skin hyper-
pigmentation due to its role in cytokine receptor signaling [51],
where alterations in p53 levels significantly affect the expression
levels of melanogenic factors. p53 plays a central role in
‘‘melanoma’’ (hsa05218) as a therapeutic agent [52] and risk
factor where certain signature hot-spot mutations in the p53 gene
result in oncogenic transformation. Among the pathways listed in
Table 4, p53 has been shown to be involved in ‘‘glioma’’
(hsa05214) [53] and ‘‘pancreatic cancer’’ (hsa5212) [54,55].
Recently, it has been shown that antigen specific (CD4+) T cell
response is critically affected by deregulation of p53 through ‘‘T
cell receptor signaling pathway’’ (hsa04660) [56]. p53 is also
known to be involved in ‘‘purine metabolism’’ (hsa00230) [57],
‘‘pyrimidine metabolism’’ (hsa00240) [58], and ‘‘fatty acid
biosynthesis’’ (hsa00061) [59,60]; other pathways identified as
active by BPA due to mutations in p53. Overall, BPA was clearly
able to identify pathways related to p53 using related microarray
data. We believe that utilized synthetic, real, and benchmark data
along with synthetic data sets render results that show the utility of
the improved BPA system as a new resource for pathway analysis
of HTBD.
Supporting Information
Table S1 Prediction accuracy of different discretization methods
on synthetic datasets. The superscripts denote the number of levels
used in the discretization method.
(DOCX)
Table S2 Lists of active pathways identified by BPA on real
cancer microarray data sets.
(DOCX)
Table S3 Lists of active pathways identified by SPIA on real
cancer microarray data sets.
(DOCX)
Table S4 Lists of active pathways identified by the old BPA on
real cancer microarray data sets.
(DOCX)
Table S5 Overlap of active pathways identified by the new and
old BPA systemson real cancer microarray data sets.
(DOCX)
Author Contributions
Conceived and designed the experiments: MK HHO. Performed the
experiments: MK SI. Analyzed the data: MK AO HHO. Contributed
reagents/materials/analysis tools: MK SI. Wrote the paper: AO HHO.
References
1. Friedman N, Linial M, Nachman I, Pe’er D (2000) Using Bayesian networks to
analyze expression data. J Comput Biol 7: 601–620.
2. Imoto S, Kim S, Goto T, Aburatani S, Tashiro K, et al. (2003) Bayesian network
and nonparametric heteroscedastic regression for nonlinear modeling of genetic
network. J Bioinform Comput Biol 1: 231–252.
3. Nam D, Kim SY (2008) Gene-set approach for expression pattern analysis. Brief
Bioinform 9: 189–197.
4. Subramanian A, Kuehn H, Gould J, Tamayo P, Mesirov JP (2007) GSEA-P: a
desktop application for Gene Set Enrichment Analysis. Bioinformatics 23: 3251–
3253.
5. Alexa A, Rahnenfuhrer J, Lengauer T (2006) Improved scoring of functional
groups from gene expression data by decorrelating GO graph structure.
Bioinformatics 22: 1600–1607.
6. Bauer S, Gagneur J, Robinson PN (2010) GOing Bayesian: model-based gene
set analysis of genome-scale data. Nucleic Acids Res 38: 3523–3532.
Table 4. Significant pathways identified by the improved BPA
system using the NCI-60 microarray data set on samples with
and without p53 mutation (p53+: 17 Samples, p532: 33
samples).
ID Name
hsa00650 Butanoate metabolism
hsa00061 Fatty acid biosynthesis
hsa05214 Glioma
hsa04916 Melanogenesis
hsa05218 Melanoma
hsa05212 Pancreatic cancer
hsa00230 Purine metabolism
hsa00240 Pyrimidine metabolism
hsa04660 T cell receptor signaling pathway
doi:10.1371/journal.pone.0102803.t004
Bayesian Pathway Analysis
PLOS ONE | www.plosone.org 7 July 2014 | Volume 9 | Issue 7 | e102803
7. Lu Y, Rosenfeld R, Simon I, Nau GJ, Bar-Joseph Z (2008) A probabilistic
generative model for GO enrichment analysis. Nucleic Acids Res 36: e109.
8. Isci S, Ozturk C, Jones J, Otu HH (2011) Pathway analysis of high-throughput
biological data within a Bayesian network framework. Bioinformatics 27: 1667–
1674.
9. Edwards D, Wang L, Sorensen P (2012) Network-enabled gene expression
analysis. BMC Bioinformatics 13: 167.
10. Li J, Wang L, Xu L, Zhang R, Huang M, et al. (2012) DBGSA: a novel method
of distance-based gene set analysis. J Hum Genet 57: 642–653.
11. Wang PI, Hwang S, Kincaid RP, Sullivan CS, Lee I, et al. (2012) RIDDLE:
reflective diffusion and local extension reveal functional associations for
unannotated gene sets via proximity in a gene network. Genome Biol 13: R125.
12. Mieczkowski J, Swiatek-Machado K, Kaminska B (2012) Identification of
pathway deregulation–gene expression based analysis of consistent signal
transduction. PLoS One 7: e41541.
13. Martini P, Sales G, Massa MS, Chiogna M, Romualdi C (2013) Along signal
paths: an empirical gene set approach exploiting pathway topology. Nucleic
Acids Res 41: e19.
14. Drier Y, Sheffer M, Domany E (2013) Pathway-based personalized analysis of
cancer. Proc Natl Acad Sci U S A 110: 6388–6393.
15. Tarca AL, Draghici S, Khatri P, Hassan SS, Mittal P, et al. (2009) A novel
signaling pathway impact analysis. Bioinformatics 25: 75–82.
16. Kanehisa M, Goto S, Sato Y, Furumichi M, Tanabe M (2012) KEGG for
integration and interpretation of large-scale molecular data sets. Nucleic Acids
Res 40: D109–114.
17. Spirtes P (1995) Directed Cyclic Graphical Representations of Feedback Models.
Proceedings of the Eleventh Conference on Uncertainty in Artificial Intelligence
(UAI-95). Morgan Kaufmann. pp. 491–549.
18. Neapolitan RE (2004) Learning Bayesian Networks. Prentice Hall.
19. Li Y, Liu L, Bai X, Cai H, Ji W, et al. (2010) Comparative study of discretization
methods of microarray data for inferring transcriptional regulatory networks.
BMC Bioinformatics 11: 520.
20. Ridler TW, Calvard S (1978) Picture thresholding using an iterative selection
method. IEEE Trans System, Man and Cybernetics SMC-8: 630–632.
21. Akaike H (1973) Information theory and an extension of the maximum
likelihood principle. Proceedings of the Second International Symposium on
Information Theory. pp. 267–281.
22. Schwarz G (1978) Estimating the dimension of a model. Annals of Statistics:
461–464.
23. Silander T, Roos T, Kontkanen P, Myllym¨aki P (2008) Factorized normalized
maximum likelihood criterion for learning Bayesian network structures. 4th
European workshop on probabilistic graphical models. Hirtshals, Denmark. pp.
257–264.
24. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, et al. (1999)
Molecular classification of cancer: class discovery and class prediction by gene
expression monitoring. Science 286: 531–537.
25. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: A practical
and powerful approach to multiple testing. J Roy Statist Soc Ser B 57: 289–300.
26. Rissanen J (1996) Fisher information and stochastic complexity. IEEE
Transactions on Information Theory 42 40–47.
27. Shtarkov YM (1987) Universal sequential coding of single messages. Problems of
Information Transmission 23: 3–17.
28. Kontkanen P, Myllyma¨ki P (2007) A linear time algorithm for computing the
multinomial stochastic complexity. Information Processing Letters 103: 227–
233.
29. Bulcke T, Van Leemput K, Naudts B, van Remortel P, Ma H, et al. (2006)
SynTReN: a generator of synthetic gene expression data for design and analysis
of structure learning algorithms. BMC Bioinformatics 7: 43.
30. Hubbell E, Liu WM, Mei R (2002) Robust estimators for expression analysis.
Bioinformatics 18: 1585–1592.
31. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005)
Gene set enrichment analysis: a knowledge-based approach for interpreting
genome-wide expression profiles. Proc Natl Acad Sci U S A 102: 15545–15550.
32. Silander T, Roos T, Myllyma¨ki P (2010) Learning locally minimax optimal
Bayesian networks. Int J Approx Reasoning 51: 544–557.
33. Okegawa T, Pong RC, Li Y, Hsieh JT (2004) The role of cell adhesion molecule
in cancer progression and its application in cancer therapy. Acta Biochim Pol 51:
445–457.
34. Cavallaro U, Christofori G (2004) Cell adhesion and signalling by cadherins and
Ig-CAMs in cancer. Nat Rev Cancer 4: 118–132.
35. Sehgal A, Boynton AL, Young RF, Vermeulen SS, Yonemura KS, et al. (1998)
Cell adhesion molecule Nr-CAM is over-expressed in human brain tumors.
Int J Cancer 76: 451–458.
36. Griffiths TR, Brotherick I, Bishop RI, White MD, McKenna DM, et al. (1996)
Cell adhesion molecules in bladder cancer: soluble serum E-cadherin correlates
with predictors of recurrence. Br J Cancer 74: 579–584.
37. Li DM, Feng YM (2011) Signaling mechanism of cell adhesion molecules in
breast cancer metastasis: potential therapeutic targets. Breast Cancer Res Treat
128: 7–21.
38. Paschos KA, Canovas D, Bird NC (2009) The role of cell adhesion molecules in
the progression of colorectal cancer and the development of liver metastasis. Cell
Signal 21: 665–674.
39. Hase T, Sato M, Yoshida K, Girard L, Takeyama Y, et al. (2011) Pivotal role of
epithelial cell adhesion molecule in the survival of lung cancer cells. Cancer Sci
102: 1493–1500.
40. Chaker S, Kak I, MacMillan C, Ralhan R, Walfish PG (2013) Activated
leukocyte cell adhesion molecule is a marker for thyroid carcinoma
aggressiveness and disease-free survival. Thyroid 23: 201–208.
41. Lane N (2009) Life ascending: the ten great inventions of evolution. New York:
Norton.
42. Mullen AR, Wheaton WW, Jin ES, Chen PH, Sullivan LB, et al. (2012)
Reductive carboxylation supports growth in tumour cells with defective
mitochondria. Nature 481: 385–388.
43. Krupp M, Maass T, Marquardt JU, Staib F, Bauer T, et al. (2011) The
functional cancer map: a systems-level synopsis of genetic deregulation in cancer.
BMC Med Genomics 4: 53.
44. Lang K, Ratke J (2009) Leptin and Adiponectin: new players in the field of
tumor cell and leukocyte migration. Cell Commun Signal 7: 27.
45. Davie CA (2008) A review of Parkinson’s disease. British medical bulletin 86:
109–127.
46. Veeriah S, Taylor BS, Meng S, Fang F, Yilmaz E, et al. (2010) Somatic
mutations of the Parkinson’s disease-associated gene PARK2 in glioblastoma
and other human malignancies. Nat Genet 42: 77–82.
47. Hayakawa K, Nagamine T (2009) Effect of fucoidan on the biotinidase kinetics
in human hepatocellular carcinoma. Anticancer research 29: 1211–1217.
48. Zastre JA, Sweet RL, Hanberry BS, Ye S (2013) Linking vitamin B1 with cancer
cell metabolism. Cancer & metabolism 1: 16.
49. Jagannathan L, Swaminathan K, Kumar SM, Kumar GR, Dey A (2012) Bio-
informatics based analysis of genes implicated in alcohol mediated liver injury.
Gene 494: 130–139.
50. Li S, Pozhitkov A, Ryan RA, Manning CS, Brown-Peterson N, et al. (2010)
Constructing a fish metabolic network model. Genome Biol 11: R115.
51. Murase D, Hachiya A, Amano Y, Ohuchi A, Kitahara T, et al. (2009) The
essential role of p53 in hyperpigmentation of the skin via regulation of paracrine
melanogenic cytokine receptor signaling. J Biol Chem 284: 4343–4353.
52. Lu M, Miller P, Lu X (2014) Restoring the tumour suppressive function of p53
as a parallel strategy in melanoma therapy. FEBS Lett.
53. England B, Huang T, Karsy M (2013) Current understanding of the role and
targeting of tumor suppressor p53 in glioblastoma multiforme. Tumour biology:
the journal of the International Society for Oncodevelopmental Biology and
Medicine 34: 2063–2074.
54. Morton JP, Timpson P, Karim SA, Ridgway RA, Athineos D, et al. (2010)
Mutant p53 drives metastasis and overcomes growth arrest/senescence in
pancreatic cancer. Proc Natl Acad Sci U S A 107: 246–251.
55. Weissmueller S, Manchado E, Saborowski M, Morris JPt, Wagenblast E, et al.
(2014) Mutant p53 drives pancreatic cancer metastasis through cell-autonomous
PDGF receptor beta signaling. Cell 157: 382–394.
56. Watanabe M, Moon KD, Vacchio MS, Hathcock KS, Hodes RJ (2014)
Downmodulation of Tumor Suppressor p53 by T Cell Receptor Signaling Is
Critical for Antigen-Specific CD4(+) T Cell Responses. Immunity 40: 681–691.
57. Bronder JL, Moran RG (2003) A defect in the p53 response pathway induced by
de novo purine synthesis inhibition. J Biol Chem 278: 48861–48871.
58. Khutornenko AA, Roudko VV, Chernyak BV, Vartapetian AB, Chumakov PM,
et al. (2010) Pyrimidine biosynthesis links mitochondrial respiration to the p53
pathway. Proc Natl Acad Sci U S A 107: 12828–12833.
59. Assaily W, Rubinger DA, Wheaton K, Lin Y, Ma W, et al. (2011) ROS-
mediated p53 induction of Lpin1 regulates fatty acid oxidation in response to
nutritional stress. Molecular cell 44: 491–501.
60. Puzio-Kuter AM (2011) The Role of p53 in Metabolic Regulation. Genes &
cancer 2: 385–391.
Bayesian Pathway Analysis
PLOS ONE | www.plosone.org 8 July 2014 | Volume 9 | Issue 7 | e102803
